logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report
      • Health Canada Priority Review & Project Orbis Sub-Report
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r.png
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report
      • Health Canada Priority Review & Project Orbis Sub-Report
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Unlocking the Future of Pharmaceutical Market Access: MORSE Consulting and Medlior Health Outcomes Research Join Forces 

September 14, 2023
-
Market Access News, What's New
-
Posted by MORSE - 2 min read.

September 14, 2023 – We are thrilled to announce a groundbreaking collaboration between MORSE Consulting and Medlior Health Outcomes Research, two leaders in the Canadian pharmaceutical market access landscape. This partnership aims to blend MORSE Consulting’s unparalleled expertise in payer and HTA strategies with Medlior’s cutting-edge real-world evidence solutions, offering our clients an unmatched array of services to navigate the complex world of pharmaceutical market access.

MORSE Consulting is a leader in Canadian market access strategy, known for its bespoke solutions and client-centric approach. With a team of professionals boasting extensive experience in payers, HTA, pCPA negotiations, and market access strategy consulting, MORSE Consulting provides unparalleled insights that set it apart from any other consultancy in Canada. Our advice is grounded in authentic and credible communication, and our comprehensive range of services, including pCPA assessment & negotiation simulation and HTA strategic advice, ensures that our clients are well-prepared for every stage of their market access journey.

Medlior is a leading independent Canadian research organization specializing in real-world evidence, health technology submissions, and evidence synthesis. Their team’s RWE expertise spans from managing ethics approval and engaging in research agreements with data custodians, to conducting complex data linkages and analyses. With a focus on client-centric project management and delivery, Medlior offers a wide range of HTA and Evidence Synthesis services, including systematic literature reviews, economic evaluations, and medical writing, tailored to meet their clients’ needs in Canada and globally.

Our first collaborative service, the Advanced Innovative Agreements/Real World Evidence (RWE) Workshop, empowers pharmaceutical companies to shape successful market access strategies. This workshop addresses the unique challenges posed by innovative therapies like cell and gene therapies, drugs for rare diseases, and precision oncology. By leveraging MORSE Consulting’s expertise in reimbursement strategy and Medlior’s expertise in real-world evidence, we offer a comprehensive and customized approach to meet the specific needs of your product. This workshop is an invaluable resource for pharmaceutical companies at any stage of drug development.

This service is just the beginning. We are actively exploring other avenues to expand our collaboration, aiming to provide even more value to our clients. If you want to learn more about how this collaborative venture can benefit your organization, please contact MORSE Consulting’s Director, Innovative Access Solutions, Sang Mi Lee (sangmi@morseconsulting.ca) or info@medlior.com for further information.

Share
Tags
Canadian Healthcare
Cell and Gene Therapies
Client-Centric Approach
Collaboration
Drugs For Rare Diseases
Economic Evaluations
Evidence Synthesis
Health Technology Assessment
Health Technology Submissions
Innovative Agreements
Innovative Therapies
Market Access Strategy
Medical Writing
Medlior
MORSE Consulting
MORSE Team
pCPA
pCPA Negotiations
Pharmaceutical Companies
Pharmaceutical Strategy
Pharmacoeconomics
Precision Oncology
Real World Evidence
Reimbursement strategy
RWD
RWE
← PREVIOUS POST
Exciting Announcement: MORSE Consulting Welcomes Ben Faienza as Strategic Advisor
NEXT POST →
MORSE Consulting Releases its pCPA Quarterly Update – Q2 2023

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Unlocking the Future of Pharmaceutical Market Access: MORSE Consulting and Medlior Health Outcomes Research Join Forces